India’s cough syrup market, worth over ₹21,800 crore in 2024, is expanding rapidly amid rising respiratory illnesses and pollution. While this growth fuels lucrative opportunities for pharmaceutical companies—both large multinationals and smaller domestic players—it simultaneously exposes alarming risks to public health due to widespread irrational drug combinations and substandard quality control, especially among smaller manufacturers.
The Profit Behind the Puff
The market’s rising demand, estimated to grow at a steady CAGR near 6%, is driven by chronic respiratory diseases and easy availability of cough syrups in retail pharmacies and online. Top brands rake in significant revenue, with the organised sector holding a major share, but nearly one-third of the market is served by SMEs with comparatively lax oversight. The unchecked proliferation of fixed-dose combinations with questionable therapeutic rationale further boosts sales volumes despite questionable clinical benefit.[1][2][6]
Patient Safety Left Behind
Recent tragic deaths of children from contaminated and irrational cough syrups have cast a stark spotlight on systemic failures. Irrational combinations—about 70-80% of products—are still widely available, risking adverse reactions and masking diseases. Quality control is critically weak among many SMEs, with inadequate GMP adherence and batch testing resulting in contaminated batches reaching vulnerable patients.[4][9][10][11]
What Needs To Change
- Stricter Regulation & Enforcement: Governments must close regulatory gaps by enforcing quality audits, mandatory batch testing, and swift sanctions against violators—particularly focusing on SMEs that make up a significant market slice.
- Rational Prescribing: Policymakers and professional bodies should aggressively promote evidence-based single-ingredient syrups and curb irrational polypharmacy, safeguarding especially the pediatric population.
- Public & Provider Education: Patients and caregivers need better awareness on the potential harms of OTC combination products. Healthcare professionals must stay vigilant to prescribe rational therapies.
- Capacity Building for SMEs: Support programs to upgrade SME manufacturing quality are critical to sustainably raise safety levels without disrupting supply.
Conclusion
While India’s cough syrup market is indeed “coughing all the way to the bank,” this success comes at a dangerous cost—not in revenue but in lives and trust. For healthcare providers and policy makers, the mandate is urgent and clear: prioritize patient safety through robust regulation, rational drug use, and public education. Only then can the market’s impressive growth become truly sustainable and life-affirming.
This is a defining moment for India’s pharmaceutical ecosystem to align commercial success with ethical responsibility and public health imperatives.
This analysis aims to guide healthcare practitioners and policymakers committed to elevating safety and standards amid India’s expanding cough syrup market.
AI Generated Images for Illustration Only. E&OE.
Sources
[1] india cough syrup market forecast 2021-2026 https://www.inkwoodresearch.com/reports/india-cough-syrup-market/
[2] Cough Syrup Market Size, Share & Trends | Forecast 2033 https://www.imarcgroup.com/cough-syrup-market
[3] Cough Syrup Market Size, Competitors & Forecast to 2030 https://www.researchandmarkets.com/report/cough-syrup
[4] WHO calls out gap in India’s cough syrup testing after deaths https://www.reuters.com/business/healthcare-pharmaceuticals/india-flags-testing-lapses-pharma-firms-after-cough-syrups-deaths-2025-10-08/
[5] Cough Syrup Market Research Report | Size, Share by 2031 https://www.theinsightpartners.com/reports/cough-syrup-market
[6] Cough Suppressant Market Size, Trends & Forecast 2025 … https://www.futuremarketinsights.com/reports/cough-suppressant-market
[7] Cough and Cold Preparations Market Report 2025 https://www.researchandmarkets.com/reports/5939623/cough-cold-preparations-market-report
[8] Cold & Cough Remedies – India | Statista Market Forecast https://www.statista.com/outlook/emo/otc-pharmaceuticals/cold-cough-remedies/india
[9] Fixed-dose Combinations for Cough and Common Cold in … https://pubmed.ncbi.nlm.nih.gov/20584201/
[10] Govt bans 14 fixed-dose combination drugs used to treat … https://www.deccanherald.com/india/govt-bans-14-fixed-dose-combination-drugs-used-to-treat-cough-fever-1224533.html
[11] CDSCO to inspect cough syrup manufacturing units https://economictimes.com/industry/healthcare/biotech/pharmaceuticals/cdsco-to-inspect-cough-syrup-manufacturing-units/articleshow/124434469.cms
